v3.25.1
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Research and development, net of grants $ 4,217 $ 3,726
General and administrative, net of grants 2,340 2,501
Total operating expenses 6,557 6,227
Loss from operations (6,557) (6,227)
Other income, net 255 188
Net loss $ (6,302) $ (6,039)
Net loss per common share - basic $ (0.11) $ (0.12)
Net loss per common share - diluted $ (0.11) $ (0.12)
Weighted average common shares outstanding - basic 59,236 52,202
Weighted average common shares outstanding - diluted 59,236 52,202

Source